4.6 Review

The FHL2 regulation in the transcriptional circuitry of human cancers

期刊

GENE
卷 572, 期 1, 页码 1-7

出版社

ELSEVIER
DOI: 10.1016/j.gene.2015.07.043

关键词

Four-and-a-half Lim (FHL2); Transcriptional regulation; Nucleus translocation; p53; Serum response factor (SRF); Specificity protein 1 (SP1); Breast cancer; Gastrointestinal cancer (Gl cancer); Liver cancer; Hepatocellular carcinoma (HCC); Prostate cancer; Bioinformatics

资金

  1. National Institutes of Health [GM089820, GM114833]
  2. Elsevier, the publisher of GENE

向作者/读者索取更多资源

The Four-and-a-half LIM (FHL)-only protein is a subfamily of protein members under the LIM-only protein family. These proteins are identified by their characteristic four and a half cysteinerich LIM homeodomain. Five members have been categorized into the FHL subfamily, which are FHL1, FHL2, FHL3, FHL4 and activator of CREM in testis (ACT) in human. FHL2 is amongst the most examined members within the family. Fhl2, the gene that code for the protein, is transcriptionally regulated by diverse types of transcription factors, for example, p53, serum response factor (SRF), and specificity protein 1 (Sp1). The expression of FHL2 is found in different tissues and organs and has been reported as a critical participant influencing the wide types of cancer such as breast cancer, gastrointestinal (GI) cancers, liver cancer and prostate cancer. The expression profile of FHL2 appeared to have a significant functional role in the carcinogenesis of these cancers which are mediated by different types of transcription factor including both tumor suppressors and inducers. In this review, we will first describe the molecular network governing FHL2 expression, which focus on the transcription factors conveying FHL2-initiated responses. In the second part, FHL2-linked cancers and the underlying molecular machinery will be discussed. Factors other than transcriptional regulation which may involve the cancer progression such as mutations of fhl2 and posttranslational modifications of the protein will also be mentioned. (C) 2015 Published by Elsevier B.V.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据